Thirona Retina, a division of the Netherlands-based Thirona, has been acquired by Icare Finland Oy, a subsidiary of the Revenio Group Corporation. This acquisition builds on a previous €1.9 million investment by Icare in 2023, leading to the full purchase of Thirona Retina for approximately €4.8 million.
The move is set to strengthen Revenio’s position in the ophthalmic diagnostics market by integrating Thirona Retina’s AI-driven RetCAD technology into its existing portfolio.
Enhancing Eye Care Through AI
The dutch firm’s RetCAD technology uses artificial intelligence to analyze color fundus images, aiding in the early detection and grading of eye diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma. By integrating this technology into Icare’s ILLUME and other retinal screening solutions, Revenio aims to improve the accuracy and efficiency of ophthalmic diagnostics. This acquisition aligns with Revenio’s growth strategy, which focuses on enhancing patient outcomes through innovative AI-based solutions.
Advertisement
Continued Collaboration and Future Plans
Despite the acquisition, Thirona Retina will continue to offer its RetCAD solutions to other vendors and AI providers, ensuring a broad impact on the eye care industry. The CEO, Jouni Toijala of the finnish firm emphasized the importance of AI in advancing ophthalmic diagnostics, noting that the addition of Thirona Retina will enable the company to develop more comprehensive AI-based solutions for clinical decision-making in eye care.
About the Companies
Founded in 2014 by Eva van Rikxoort, Thirona specializes in AI-assisted medical image analysis, focusing on both retinal and lung images to detect and quantify anomalies. Thirona’s AI technology is currently used in over 600 hospitals worldwide, supporting clinicians in delivering high-quality patient care.
Revenio Group, listed on Nasdaq Helsinki, is a global leader in eye care diagnostics, offering a range of products including intraocular pressure measurement devices, fundus imaging systems, and perimeters under the iCare brand. The acquisition of the dutch company marks another step in the commitment to advancing eye care through technology and innovation.
